summary
Introduced
09/25/2020
09/25/2020
In Committee
09/25/2020
09/25/2020
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
To amend the Internal Revenue Code of 1986 to deny the deduction for advertising and promotional expenses for prescription drugs. This bill prohibits tax deductions for expenses relating to direct-to-consumer advertising of prescription drugs. Direct-to-consumer advertising is any dissemination, by or on behalf of a sponsor of a prescription drug product, of an advertisement that is (1) in regard to the drug product, and (2) primarily targeted to the general public.
AI Summary
This bill, the End Taxpayer Subsidies for Drug Ads Act, amends the Internal Revenue Code to disallow tax deductions for expenses related to direct-to-consumer advertising of prescription drugs. Direct-to-consumer advertising refers to any dissemination of advertisements about a prescription drug product that is primarily targeted to the general public, such as through publications, broadcasting, and digital platforms. By prohibiting tax deductions for these advertising expenses, the bill aims to eliminate taxpayer subsidies for such prescription drug marketing.
Committee Categories
Budget and Finance
Sponsors (3)
Last Action
Referred to the House Committee on Ways and Means. (on 09/25/2020)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/house-bill/8399/all-info |
| BillText | https://www.congress.gov/116/bills/hr8399/BILLS-116hr8399ih.pdf |
| Bill | https://www.congress.gov/116/bills/hr8399/BILLS-116hr8399ih.pdf.pdf |
Loading...